Immune-checkpoint inhibitors (ICIs) have dramatically changed the management of
advanced cancers. Designed to enhance the antitumour immune response, they can also …

The use of immune checkpoint inhibitors (ICIs) has evolved rapidly with unprecedented
treatment benefits being obtained for cancer patients, including improved patient survival …

Blockade of immune checkpoints has transformed the therapy of several cancers. However,
immune‐related adverse events (irAEs) have emerged as a major challenge limiting the …

While experimental and informatic techniques around single cell sequencing (scRNA-seq)
are advanced, research around mass cytometry (CyTOF) data analysis has severely lagged …

Cancer survival and progression depend on the ability of tumor cells to avoid immune
recognition. Advances in the understanding of cancer immunity and tumor immune escape …

There is a lack of reliable biomarkers to predict and identify the risk of immune-related
adverse events (irAEs) in non-small cell lung cancer (NSCLC) patients undergoing immune …

Profiling the binding of T cell receptors (TCRs) of T cells to antigenic peptides presented by
MHC proteins is one of the most important unsolved problems in modern immunology …

Recently developed single-cell profiling technologies, such as single cell sequencing
(scRNA-seq) and mass cytometry (CyTOF), provide critical biological insights from a large …

Hintergrund Immun-Checkpoint-und BRAF-/MEK-Inhibitoren (ICI) haben eine zentrale
Stellung in der Krebstherapie eingenommen, da sie eine erhebliche Lebensverlängerung …

Background and purpose: Immune checkpoint inhibitors (ICIs) have changed the landscape
of cancer treatment during the last 10 years. They have significantly extended survival for …